Clinical Trial Update: Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander Cell Line for Tumor Vaccine in Melanoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating a universal GM-CSF-producing and CD40L-expressing bystander cell line as a tumor vaccine for melanoma; the study has completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Universal GM-CSF-producing and CD40L-expressing bystander cell line

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED | Results posted: 2012-11-16